Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis
详细信息 查看全文
- 作者：Masaki Akimoto (1)
Shingo Yunoue (2)
Hideo Otsubo (3)
Tamami Yoshitama (3)
Kunihiro Kodama (3)
Kakushi Matsushita (1)
Yukio Suruga (1)
Tomohiro Kozako (2)
Shingo Toji (4)
Sachi Hashimoto (4)
Kimiharu Uozumi (1) (2)
Takemasa Matsuda (3)
Naomichi Arima (1) (2) - 关键词：CD4+ cell ; ImmuKnow ; Immune cell function ; Infection ; Rheumatoid arthritis
- 刊名：Modern Rheumatology
- 出版年：2013
- 出版时间：January 2013
- 年：2013
- 卷：23
- 期：1
- 页码：19-27
- 参考文献：1. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663-. CrossRef
2. Sanchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernandez-Fresnedo G, Lopez-Hoyos M, et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22:55-0.
3. Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser PA, et al. Utility of the Cylex assay in cardiac transplant recipients. J Heart Lung Transplant. 2008;27:817-2. CrossRef
4. Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant. 2008;27:990-. CrossRef
5. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-8. CrossRef
6. Serban G, Whittaker V, Fan J, Liu Z, Manga K, Khan M, et al. Significance of immune cell function monitoring in renal transplantation after thymoglobulin induction therapy. Hum Immunol. 2009;70:882-0. CrossRef
7. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV / Pneumocystis carinii pneumonia. Chest. 1998;113:1215-4. CrossRef
8. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J. / Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-1.
9. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-5. CrossRef
10. Balandraud N, Roudier J, Roudier C. What are the links between Epstein–Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum. 2005;34:31-. CrossRef
11. Dias C, Isenberg DA. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma. Nat Rev Rheumatol. 2011;7:360-. CrossRef
12. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-2. CrossRef
13. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang Y, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1. CrossRef
14. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17:366-. CrossRef
15. Acosta-Rodriguez EV, Napoletani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007;8:942-. CrossRef
16. Chen Z, Tato CM, Muul L, Laurence A, O’Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56:2936-6. CrossRef
17. Wilson NJ, Boniface K, Chan JR, McKenzie B, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950-. CrossRef
18. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat SAJ, et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity. 2007;27:1-0. CrossRef
19. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28:454-7. CrossRef
20. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46:1157-0. CrossRef
21. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-1. CrossRef
22. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007;66:308-2. CrossRef
23. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-00. CrossRef
24. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387-3.
25. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628-4. CrossRef
26. Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57:1151-. CrossRef
27. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis. 2011;70:956-0. CrossRef
28. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA. 1991;88:2441-. CrossRef - 作者单位：Masaki Akimoto (1)
Shingo Yunoue (2)
Hideo Otsubo (3)
Tamami Yoshitama (3)
Kunihiro Kodama (3)
Kakushi Matsushita (1)
Yukio Suruga (1)
Tomohiro Kozako (2)
Shingo Toji (4)
Sachi Hashimoto (4)
Kimiharu Uozumi (1) (2)
Takemasa Matsuda (3)
Naomichi Arima (1) (2)
1. Department of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan
2. Division of Hematology and Immunology, Center for Chronic Viral Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan
3. Rheumatic Disease Unit, Japanese Red Cross Kagoshima Hospital, Kagoshima, Japan
4. Medical and Biological Laboratories, Nagoya, Japan - ISSN：1439-7609
文摘
Objective The ability of the ImmuKnow (Cylex) assay to predict the risk of infection in rheumatoid arthritis (RA) patients receiving synthetic or biological disease-modifying antirheumatic drugs (DMARDs) was examined. Methods The amount of adenosine triphosphate (ATP) produced by CD4+ cells in response to phytohemagglutinin was measured in whole blood from 117 RA patients without infection versus 17 RA patients with infection, and compared with results in 75 healthy controls. Results The mean ATP level was significantly lower in patients with infection compared to both healthy controls (P?<?0.0005) and patients without infection (P?=?0.040). Also, the mean ATP level in patients without infection was significantly lower than that in healthy controls (P?=?0.012). There was no correlation between the ATP level and the Disease Activity Score in 28 joints. Conclusion ImmuKnow assay results may be effective in identifying RA patients at increased risk of infection, but the results showed no correlation with RA activity. Larger studies are required to establish the clinical advantages of this assay in RA treatment.